Piper Sandler analyst Edward Tenthoff assumedcoverage of Biomea Fusion (BMEA) with an Overweight rating and $7 price target The company is developing icovamenib to treat diabetes, a covalent menin inhibitor, the analyst tells investors in a research note. Piper views Biomea as an emerging diabetes and obesity play.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: